GLUECK, Reinhard,FAZIO, Agata,GIANINO, Viviana,BILLETER, Martin
申请号：
AU2014201356
公开号：
AU2014201356A1
申请日:
2014.03.11
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
#$%^&*AU2014201356A120140529.pdf#####ABSTRACT: The present invention relates to a combined measles-malaria vaccine containing different attenuated recombinant measles-malaria 5 vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP1) of P. falciparum, and its derivatives (p-42； p-83-30-38) in its 10 glycosylated and secreted forms, and apical membrane antigen 1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells 15 efficiently. In a preferred embodiment, the CS, the MSP1 and the AMA1 proteins are generated from the virus such that they will give rise to a potent immune response in mammals, preferably humans； the expression of the proteins is elevated due to human codon optimisation. Furthermore, the invention relates to the use of the 20 recombinant vaccine in the prophylactic treatment of malaria. 5190235_1 (GHMatters) P88715.AU.1 11-Mar-14
